Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
Rev. Soc. Bras. Med. Trop
;
53: e20190594, 2020. tab, graf
Article
Dans Anglais
| SES-SP, ColecionaSUS, LILACS
| ID: biblio-1136866
ABSTRACT
Abstract INTRODUCTION We conducted a cost-utility analysis of available interferon-free treatments for patients with early-stage genotype 1 chronic hepatitis C based on a Brazilian public health system perspective. METHODS A Markov model was derived using a cohort of stage F0-F2 patients treated as recommended by the Brazilian national guidelines. RESULTS:
Glecaprevir plus pibrentasvir was superior to all other treatments, followed by sofosbuvir plus velpatasvir. Sofosbuvir plus daclatasvir was identified as the least cost-effective option.CONCLUSIONS:
The above findings were confirmed via probabilistic sensitivity analysis and the tested scenarios.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Antiviraux
/
Hepacivirus
/
Hépatite C chronique
/
Association de médicaments
Type d'étude:
Guide de pratique
/
Évaluation en économique de la santé
/
Étude pronostique
Limites du sujet:
Humains
Pays comme sujet:
Amérique du Sud
/
Brésil
langue:
Anglais
Texte intégral:
Rev. Soc. Bras. Med. Trop
Année:
2020
Type:
Article
Institution/Pays d'affiliation:
Universidade Federal do Paraná/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS